50-50 or BioNTech and the Pfizer Illusion
How many people know that Pfizer splits its profits on sales of what is commonly known as the “Pfizer” Covid-19 vaccine 50-50 with the German firm BioNTech? And that is just Pfizer-branded sales. BioNTech also has reserved markets in which it sells the vaccine (if it is a vaccine) directly under its own name, and it also earns a profit share on sales by the Chinese firm Fosun Pharma in Hong Kong.
As a result, BioNTech’s profits on sales of the so-called “Pfizer” vaccine are in fact far greater than Pfizer’s! Roughly 15 billion dollars (or euros) as compared to 10 billion in 2021.
So, why in the world is the product even referred to as the “Pfizer” vaccine? This is obviously a misnomer. It is BioNTech’s vaccine. Pfizer merely manufactures and sells it in certain (but not all) markets on BioNTech’s behalf
For details, documentation and a discussion of why getting the name right matters, see my new article for the Brownstone Institute here.